SCHEMBL10132633

SCHEMBL10132633

O=C(NCc1ccccc1)c1ccc2c(c1)[nH]c(=O)c1ccsc12

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.65
CSNK2A2 P19784 1/20 0.65
CSNK2B P67870 1/20 0.65
CSNK2A1 P68400 1/20 0.65
IMPDH2 P12268 1/20 0.63
KDM4E B2RXH2 4/20 0.55
ALDH1A1 P00352 4/20 0.55
GLA P06280 2/20 0.55
GAA P10253 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
TP53 P04637 2/20 0.52
MAPT P10636 2/20 0.52
RXFP1 Q9HBX9 2/20 0.49
HTT P42858 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ITK Q08881 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10132647 0.89 PARP1 (0.66) PARP1CSNK2A2CSNK2BCSNK2A1IMPDH2
SCHEMBL10132650 0.89 PARP1 (0.59) PARP1CSNK2A2CSNK2BCSNK2A1IMPDH2
SCHEMBL10132651 0.88 TSHR (0.59) PARP1CSNK2A2CSNK2BCSNK2A1IMPDH2
SCHEMBL10132584 0.86 MAPT (0.58) PARP1CSNK2A2CSNK2BCSNK2A1KDM4E
SCHEMBL13648695 0.86 PARP1 (0.58) PARP1CSNK2A2CSNK2BCSNK2A1IMPDH2
SCHEMBL10132645 0.85 KDM4E (0.57) PARP1CSNK2A2CSNK2BCSNK2A1KDM4E
SCHEMBL10132659 0.85 PARP1 (0.69) PARP1CSNK2A2CSNK2BCSNK2A1IMPDH2
SCHEMBL10132666 0.83 PARP1 (0.66) PARP1CSNK2A2CSNK2BCSNK2A1IMPDH2
SCHEMBL10132587 0.83 PARP1 (0.69) PARP1CSNK2A2CSNK2BCSNK2A1TP53
SCHEMBL10132641 0.83 MAPT (0.59) PARP1CSNK2A2CSNK2BCSNK2A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062043-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES, INC. (TW) 2015-06-23 US disclosed
US-9062043-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES, INC. (TW) 2015-06-23 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20110263581-A1 FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2011-10-27 US disclosed
US-20110263581-A1 FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2011-10-27 US disclosed
US-7956064-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators CYLENE PHARMACEUTICALS, INC. (US) 2011-06-07 US disclosed
US-7956064-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators CYLENE PHARMACEUTICALS, INC. (US) 2011-06-07 US disclosed
US-20090264423-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-10-22 US disclosed
US-20090264423-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-10-22 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
WO-2009108912-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-09-03 WO disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
WO-2008028168-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263581-A1 FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS PARP1, PARP11, TNKS PARP1 1/4885CSNK2A2 90/4885CSNK2B 105/4885
US-20090264423-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS PACSIN2, TNKS, PARP1 PARP1 3/4885CSNK2A2 37/4885CSNK2B 39/4885
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 PARP1 690/4885CSNK2A2 810/4885CSNK2B 772/4885
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS PACSIN2, TNKS, PARP1 PARP1 3/4885CSNK2A2 37/4885CSNK2B 39/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 PARP1 690/4885CSNK2A2 810/4885CSNK2B 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.